This early-stage trial tests a one-time gene therapy injection (NG101) for wet age-related macular degeneration. The therapy uses a harmless virus to deliver a gene that makes a drug inside the eye, aiming to reduce the need for repeated anti-VEGF injections. About 20 adults aged…
Phase 1/2 • Sponsor: Elisigen, Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC